Carolyn Coleman
Family · Jonesboro, ARNPI 1407388267
Payments from drug & device makers
Across 60 payments — averaging $50.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$623
- Amgen$301
- AbbVie$211
- Merck$207
- GSK$190
- Axsome Therapeutics, Inc.$179
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,058100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $623 |
| Amgen | 5 | $301 |
| AbbVie | 4 | $211 |
| Merck | 11 | $207 |
| GSK | 2 | $190 |
| Axsome Therapeutics, Inc. | 2 | $179 |
| Impel Pharmaceuticals Inc. | 5 | $153 |
| Lilly USA, LLC | 4 | $141 |
| Johnson & Johnson | 3 | $135 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 2 | $104 |
| Lantheus Medical Imaging, Inc. | 1 | $93 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Corium, LLC | 1 | $89 |
| Neurelis, Inc. | 1 | $88 |
| AstraZeneca | 1 | $87 |
| Genentech USA, Inc. | 1 | $86 |
| Viiv Healthcare Company | 2 | $40 |
| Mission Pharmacal Company | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$122
How this compares
$3,058 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $64,023 |
| OzempicSemaglutide | 13 | $16,454 |
| EliquisApixaban | 12 | $7,882 |
| Ondansetron OdtOndansetron | 15 | $317 |
| Pantoprazole Sodium | 31 | $300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $209 |
| Gabapentin | 17 | $191 |
| Atorvastatin Calcium | 38 | $183 |
| Buspirone Hcl | 16 | $174 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 14 | $131 |
| Amlodipine Besylate | 18 | $119 |
| Furosemide | 27 | $117 |
| Metoprolol Succinate | 13 | $96 |
| Allopurinol | 20 | $79 |
| Zolpidem Tartrate | 15 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $141 | $64,02356 claims |
| Novo NordiskOzempic | $623 | $16,45413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.
Other family in Jonesboro
- Stefanie BrackinJonesboro$51K
- Jessica MatthewsJonesboro$19K
- Kimberly DanielsJonesboro$14K
- Kimberly RoddyJonesboro$12K
- Christopher JordanJonesboro$12K
- Amber ToombsJonesboro$12K
- Tracy ThompsonJonesboro$11K
- Ashley SheltonJonesboro$10K
- Steven VanderbiltJonesboro$10K
- Erika VanceJonesboro$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.